The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prevalence and landscape of actionable genomic alterations in renal cell carcinoma.
 
Kyrollis Attalla
No Relationships to Disclose
 
Renzo G. DiNatale
No Relationships to Disclose
 
Eduard Reznik
No Relationships to Disclose
 
Christopher Fong
No Relationships to Disclose
 
Francisco Sanchez-Vega
No Relationships to Disclose
 
Andrew W. Silagy
No Relationships to Disclose
 
Stanley Weng
No Relationships to Disclose
 
Jonathan Coleman
Travel, Accommodations, Expenses - Digital Angiography Reading Center (I)
Other Relationship - Steba Biotech
 
Chung-Han Lee
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Calithera Biosciences; Eisai; Eisai
 
Maria Isabel Carlo
Consulting or Advisory Role - Pfizer
Other Relationship - Prostate Cancer Foundation; Robert Wood Johnson Foundation
 
Paul Russo
No Relationships to Disclose
 
Timothy An-thy Chan
Leadership - Bristol-Myers Squibb; Cancer Genetics; Illumina
Stock and Other Ownership Interests - Gritstone Bio
Research Funding - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Neoantigen discovery and genomic biomarkers for immunotherapy response
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Incyte; Lilly; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); Novartis (Inst); Pfizer (Inst)
 
Nikolaus D. Schultz
No Relationships to Disclose
 
Martin H Voss
Stock and Other Ownership Interests - CellGenix (I)
Consulting or Advisory Role - Alexion Pharmaceuticals; Calithera Biosciences; Corvus Pharmaceuticals; Eisai; Exelixis; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Genentech/Roche; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Eisai; Takeda
 
A. Ari Hakimi
No Relationships to Disclose